Otsuka submits Japanese NDA for nalmefene to treat alcohol dependence

In October, Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) submitted a Japanese NDA for nalmefene to treat alcohol dependence. Otsuka and H. Lundbeck A/S (CSE:LUN) co-developed nalmefene for alcohol dependency in Japan. It is marketed as Selincro in the EU to help reduce alcohol consumption in adults with alcohol dependence as an adjuvant to psychosocial support (see BioCentury, Nov. 11, 2013)...